A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
o This company is a biotech/drug company that is a small cap. It has buy and outperform analyst ratings, a P/E of 16.4x, its chart shows nice growth, and the technical analysis looks fairly bullish on this one. Also, this stock is beating all of its competitors in stock growth by about 100% and is starting to pull steadily above the S&P 500 growth. It has solid profitability, an extremely nice EPS growth rate of 241.5 (>98% of peers), and 25% internal ownership. Furthermore, with Obamacare, I am assuming SCLN will benefit from the healthcare bill. Earnings growth is the only thing that is not outstanding on this stock: it is steady growth but nothing extraordinary. I still like this one though.